Compare Cassava Sciences Inc (FLNA) vs Oklo Inc (OKLO) Price & Performance

Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.

The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.

OKLO trades at $42.80, down 7.44% in the last session amid a bearish technical signal. The company continues to report losses with negative ROE and ROA, though it maintains strong analyst support with a consensus price target of $90.88. Recent news highlights regulatory progress for its nuclear reactors and partnerships, but the stock faces volatility as it navigates funding and approval timelines.

Long-term potential hinges on successful reactor deployment and regulatory clearances, offering significant upside if execution improves. Key risks include persistent cash burn, regulatory delays, and high valuation multiples without current profitability, requiring careful risk assessment by investors.